Northland Securities Estimates TLSI FY2025 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities research analysts at Northland Securities issued their FY2025 earnings per share (EPS) estimates for TriSalus Life Sciences in a report released on Monday, March 2nd. Northland Securities analyst C. Byrnes expects that the company will post earnings per share of ($0.85) for the year. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The business had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group raised their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.77 on Wednesday. The stock has a market cap of $238.79 million, a price-to-earnings ratio of -2.36 and a beta of 0.42. The company has a 50 day moving average of $5.41 and a 200-day moving average of $5.36. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.95.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $10,900,000. AWM Investment Company Inc. bought a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $6,812,000. Vanguard Group Inc. raised its holdings in TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after buying an additional 345,186 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its stake in TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 107.4% in the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares during the period. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences News Summary

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Company reaffirmed 2026 revenue guidance of $60.0M–$62.0M and said it is expanding its PEDD (peripheral embolization and device-directed delivery) portfolio — a signal of expected top-line growth that topped consensus revenue expectations and supports 2026 revenue momentum. TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
• Positive Sentiment: Lake Street reiterated its Buy rating on TLSI, which can help support investor confidence after the quarter. Lake Street Sticks to Its Buy Rating for TriSalus Life Sciences (TLSI)
• Neutral Sentiment: Q4 revenue came in at $13.21M, essentially matching analyst estimates ($13.20M), so top-line execution was steady even as profitability remains negative. TriSalus Q4 / Year-End 2025 Results Press Release
• Neutral Sentiment: Management held an earnings call and the transcript is available for details on product rollout and commercialization plans—useful for assessing execution risk vs. guidance assumptions. TriSalus (TLSI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Research note: Northland updated its FY2025 EPS estimate (C. Byrnes: ($0.85) vs. the consensus of ($1.55)), indicating analysts are still modeling losses but there’s variation in expectations. Northland Securities FY2025 EPS Estimate for TriSalus
• Negative Sentiment: TriSalus missed on Q4 EPS: reported ($0.21) vs. consensus ($0.13), a material EPS shortfall that pressures sentiment and valuation given the company remains unprofitable. TriSalus Q4 EPS Miss and Conference Call
• Negative Sentiment: Technicals and liquidity: TLSI is trading below its 50- and 200-day simple moving averages and volume is elevated versus average—these factors can amplify downside pressure in the near term.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.